Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H009
- Development stage
- Phase 3
- Lead developer
- Nanjing Carephar Shenghui Pharmaceutical
- Administration
- Injection
01
Overview
H009 is an investigational drug administered via injection, currently undergoing a Phase II clinical study for the treatment of bleeding caused by acute gastric and duodenal ulcers of the upper digestive tract. It is also being developed for the assisted eradication of Helicobacter Pylori. The drug is being developed by Nanjing Carephar shenghui Pharmaceutical Co., Ltd.
Beyond the preview
Go deeper on H009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H009.